Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Topline save search
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE 4 | $41.95 0.84% 340K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | News | $13.46 7.08% 610K
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 15:00) - hancockjaffe.com
NVNO | $4.8 4.6K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -2.06%
venovalve symposium topline medical trial
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
NVNO | $4.8 4.6K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -2.06%
symposium topline medical trial
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.91 -2.8% 57K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Published: 2024-04-11 (Crawled : 19:00) - globenewswire.com
ENLV | $1.42 -4.05% 51K
|
Health Technology
|
| O: 3.28%
H: 2.12%
C: -16.4%
topline trial results
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
ENLV | $1.42 -4.05% 51K
|
Health Technology
|
| O: -44.19%
H: 1.36%
C: -17.19%
topline trial results
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
INZY | $4.76 2.37% 90K
|
Health Technology
|
| O: 2.2%
H: 7.69%
C: -9.69%
inz-701 pharma positive ongoing trials topline
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.88 -0.53% 31K
|
|
| O: -76.55%
H: 13.89%
C: -17.78%
lung cancer cell topline trial therapeutics results
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
VIRX | $0.91 -2.8% 57K
|
Manufacturing
|
| O: 0.96%
H: 8.57%
C: 5.71%
congress topline trial therapeutics results
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Published: 2024-03-26 (Crawled : 12:30) - globenewswire.com
INZY | $4.76 2.37% 90K
|
Health Technology
|
| O: 2.09%
H: 14.47%
C: 6.6%
inz-701 pharma report ongoing trials topline
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
FEMY | $1.31 0.77% 34K
|
Manufacturing
|
| O: -6.5%
H: 0.53%
C: -3.74%
femaseed positive treatment topline trial
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
CERS | $1.69 3.05% 200K
|
Health Technology
|
| O: 12.9%
H: 5.71%
C: -2.86%
corporation positive blood system topline trial cardiovascular results
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
IMRX | $1.89 1.61% 49K
|
|
| O: -21.09%
H: 7.96%
C: -37.5%
tumors positive topline trial results
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
CRNX | $44.04 0.07% 140K
|
Health Technology
|
| O: 0.81%
H: 2.03%
C: -1.41%
positive treatment topline trial results
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.3 -1.71% 53K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
NVNO | $4.8 4.6K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 positive topline meeting trial today
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - hancockjaffe.com
NVNO | $4.8 4.6K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 venovalve positive topline meeting trial today
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
TARS | $33.63 -2.3% 57K
|
Health Technology
|
| O: -0.43%
H: 6.07%
C: 5.13%
tp-05 disease positive topline trial results
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
Published: 2024-02-20 (Crawled : 14:00) - biospace.com/
NVNO | $4.8 4.6K
|
Manufacturing
|
| O: 2.59%
H: 15.53%
C: 7.18%
enous2024 topline meeting medical trial
Gainers vs Losers
| 82% | 18% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
SMSI 4 | $2.53 29.74% 510K
|
Technology Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.